PAPERS - RESEARCH FRONT: 3
| TITLE | 1ST AUTHOR | YEAR |
| Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease |
Korth C |
2001 |
| Identification of the heparan sulfate binding sites in the cellular prion protein |
Warner RG |
2002 |
| Potential risk of bovine spongiform encephalopathy (BSE) to human beings and therapeutic approaches to prion disease |
Kaneko K |
2002 |
| Glycosaminoglycans and beta-amyloid, prion and tau peptides in neurodegenerative diseases |
Diaz-Nido J |
2002 |
| Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model |
Collins SJ |
2002 |
| Protein conformation and diagnostic tests: The prion protein |
Bennion BJ |
2002 |
| Potent inhibition of scrapie prion replication in cultured cells by bis-acridines |
May BCH |
2003 |
| Potential treatments and treatment strategies in Creutzfeldt-Jakob disease |
Macleod MA |
2003 |
| Pentosan polysulfate as a prophylactic and therapeutic agent against prion disease |
Dealler S |
2003 |
| Differential inhibition of prion propagation by enantiorners of quinacrine |
Ryou C |
2003 |
| Therapeutic approaches in prion disease |
Hachiya NS |
2003 |
| Prion diseases: From molecular biology to intervention strategies |
Nunziante M |
2003 |
| Prion diseases and the "protein only" hypothesis |
Zhou JM |
2004 |
| Quinoline derivatives are therapeutic candidates for transmissible spongiform encephalopathies |
Murakami-Kubo I |
2004 |
| Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrP degradation |
Perrier V |
2004 |
| Prion diseases - Close to effective therapy? |
Cashman NR |
2004 |
| Inhibition of PrPSc formation by lentiviral gene transfer of PrP containing dominant negative mutations |
Crozet C |
2004 |
| Pharmacokinetics of quinacrine in the treatment of prion disease |
Yung L |
2004 |
| Semiautomated cell-free conversion of prion protein: Applications for high-throughput screening of potential antiprion drugs |
Breydo L |
2005 |
| PrPSc incorporation to cells requires endogenous glycosaminoglycan expression |
Hijazi N |
2005 |